REGENXBIO’s Late-Stage Pipeline Momentum Strengthens After Q3 Earnings Beat (NASDAQ:RGNX)

Core Insights - REGENXBIO Inc. reported a GAAP EPS loss of -$1.20 for Q3 2025, which exceeded estimates by approximately $0.14 [1] - The company's revenue for the same quarter was $29.7 million, reflecting a year-over-year increase of 22.7% and surpassing expectations by about $5.29 million [1] Financial Performance - Q3 2025 GAAP EPS loss: -$1.20, beating estimates by $0.14 [1] - Revenue: $29.7 million, up 22.7% year-over-year, exceeding expectations by $5.29 million [1]